CTLA4 and neoplasm: Immune checkpoint blockade (ICB) represents a novel groundbreaking tumor immunotherapy that targets two key immune checkpoint pathways programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) and cytotoxic T lymphocyte-associated protein 4/B7 (CTLA-4/B7).